Trials / Terminated
TerminatedNCT01647789
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was supposed to have assessed the safety and preliminary antitumor activity of CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are abiraterone naive or abiraterone resistant. The study was terminated after Phase I (dose escalation phase) and Phase II part of the study was not initiated. Novartis voluntarily terminated this study and hence stopped further enrollment of patients into this study. As the decision to terminate the study was not due to any safety issues, the patients enrolled in the study by the time of this decision were allowed to continue with treatment per the protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CFG920 |
Timeline
- Start date
- 2012-12-04
- Primary completion
- 2016-02-03
- Completion
- 2016-02-03
- First posted
- 2012-07-24
- Last updated
- 2018-08-03
Locations
7 sites across 4 countries: United States, Belgium, Canada, Spain
Source: ClinicalTrials.gov record NCT01647789. Inclusion in this directory is not an endorsement.